Phase 3 X-TOLE2 topline data for azetukalner in FOS expected first half of March 2026Five additional Phase 3 studies of azetukalner continue to ...

Christina Gentry, DVM, DACVM, discusses dermatologic signs that a patient is in need of immediate attention, including ...

Company surpassed $2 billion in GMV, accelerated active buyer growth, and exceeded 2025 financial guidance SAN FRANCISCO, Feb ...

Standard Motor Products, Inc. ( SMP) Q4 2025 Earnings Call February 26, 2026 11:00 AM EST ...

ORLANDO, Fla., Feb. 26, 2026 /PRNewswire/ — United Parks & Resorts Inc. (NYSE: PRKS), a leading theme park and entertainment company, today reported its financial results for the fourth quarter and ...

AbCellera Biologics Inc. (NASDAQ: ABCL) Q4 2025 Earnings Call Transcript February 24, 2026 AbCellera Biologics Inc. beats ...

Warby Parker Inc. (NYSE: WRBY) ("Warby Parker" or the "Company"), a direct-to-consumer lifestyle brand focused on vision for all, today announced financial results for the fourth quarter and full year ...

Remaining Performance Obligations as of December 31, 2025 reached a new record of $1,106.0 million driven by strong bookings during the quarter and a book-to-bill ratio of 1.3x. Bookings were driven ...

Delivered Q4 and FY2025 revenue above guidanceBest ARR performance of the year in Q4 with total ending ARR of $124 millionRecord percentage of ARR in multi-year agreements and record number of ...

Sarepta Therapeutics, Inc. ( SRPT) Q4 2025 Earnings Call February 25, 2026 4:30 PM EST ...

GAAP operating loss in the fourth quarter of 2025 was $20.1 million compared to operating loss of $12.4 million in the fourth quarter of 2024. Non-GAAP operating loss was $15.2 million in the fourth ...

Durable royalties portfolio generated $58.4 million in revenue for the fourth quarter and $250.3 million for the full yearIST achieved U.S. net product sales of $33.9 million for the fourth quarter ...